BioMark Diagnostics Announces Uplisting to OTCQB Venture Market
BioMark Diagnostics (CSE: BUX) (OTCQB: BMKDF) has announced its uplisting from the OTC Pink Open Market to the OTCQB Venture Market effective May 8th, 2025. The company, which develops liquid biopsy tests for early cancer detection, will maintain its DTC eligibility for electronic clearing and settlement in the United States. The stock will continue trading on the Canadian Securities Exchange under "BUX" with no action required from current shareholders.
CEO Rashid Bux highlighted this uplisting as a strategic move to increase visibility among U.S. investors and enhance stock liquidity. The timing aligns with BioMark's plans to commercially launch its liquid biopsy test for lung cancer and expand operations in the U.S. through potential collaborations with comprehensive cancer screening centers.
BioMark Diagnostics (CSE: BUX) (OTCQB: BMKDF) ha annunciato il suo passaggio dall'OTC Pink Open Market all'OTCQB Venture Market, a partire dall'8 maggio 2025. L'azienda, che sviluppa test di biopsia liquida per la diagnosi precoce del cancro, manterrà la sua idoneità DTC per la compensazione elettronica negli Stati Uniti. Le azioni continueranno a essere quotate sulla Canadian Securities Exchange con il simbolo "BUX", senza necessità di azioni da parte degli attuali azionisti.
Il CEO Rashid Bux ha sottolineato che questo passaggio rappresenta una mossa strategica per aumentare la visibilità tra gli investitori statunitensi e migliorare la liquidità delle azioni. Il tempismo coincide con i piani di BioMark di lanciare commercialmente il test di biopsia liquida per il cancro ai polmoni e di espandere le operazioni negli Stati Uniti tramite potenziali collaborazioni con centri di screening oncologico completi.
BioMark Diagnostics (CSE: BUX) (OTCQB: BMKDF) ha anunciado su ascenso desde el OTC Pink Open Market al OTCQB Venture Market, efectivo a partir del 8 de mayo de 2025. La compañía, que desarrolla pruebas de biopsia líquida para la detección temprana del cáncer, mantendrá su elegibilidad DTC para compensación y liquidación electrónica en Estados Unidos. Las acciones continuarán cotizando en la Bolsa de Valores de Canadá bajo el símbolo "BUX", sin que los accionistas actuales deban tomar ninguna acción.
El CEO Rashid Bux destacó que esta subida es un movimiento estratégico para aumentar la visibilidad entre los inversores estadounidenses y mejorar la liquidez de las acciones. El momento coincide con los planes de BioMark de lanzar comercialmente su prueba de biopsia líquida para el cáncer de pulmón y expandir sus operaciones en EE. UU. mediante posibles colaboraciones con centros integrales de detección de cáncer.
BioMark Diagnostics (CSE: BUX) (OTCQB: BMKDF)는 2025년 5월 8일부로 OTC 핑크 오픈 마켓에서 OTCQB 벤처 마켓으로 상장 이전을 발표했습니다. 조기 암 진단을 위한 액체 생검 검사를 개발하는 이 회사는 미국 내 전자 결제 및 정산을 위한 DTC 적격성을 유지할 예정입니다. 주식은 캐나다 증권 거래소에서 "BUX"로 계속 거래되며, 기존 주주들은 별도의 조치를 취할 필요가 없습니다.
CEO Rashid Bux는 이번 상장 이전이 미국 투자자들 사이에서 가시성을 높이고 주식 유동성을 강화하기 위한 전략적 조치라고 강조했습니다. 이 시기는 BioMark가 폐암 액체 생검 검사를 상업적으로 출시하고, 포괄적인 암 검진 센터와의 잠재적 협력을 통해 미국 내 사업을 확장하려는 계획과 맞물립니다.
BioMark Diagnostics (CSE : BUX) (OTCQB : BMKDF) a annoncé son passage de l'OTC Pink Open Market au OTCQB Venture Market, effectif à partir du 8 mai 2025. L'entreprise, qui développe des tests de biopsie liquide pour la détection précoce du cancer, conservera son éligibilité DTC pour la compensation et le règlement électroniques aux États-Unis. L'action continuera d'être négociée sur la Bourse des valeurs canadienne sous le symbole "BUX", sans qu'aucune action ne soit requise de la part des actionnaires actuels.
Le PDG Rashid Bux a souligné que cette montée en gamme constitue une démarche stratégique visant à accroître la visibilité auprès des investisseurs américains et à améliorer la liquidité de l'action. Ce timing coïncide avec les projets de BioMark de lancer commercialement son test de biopsie liquide pour le cancer du poumon et d'étendre ses opérations aux États-Unis grâce à d'éventuelles collaborations avec des centres complets de dépistage du cancer.
BioMark Diagnostics (CSE: BUX) (OTCQB: BMKDF) hat seinen Wechsel vom OTC Pink Open Market zum OTCQB Venture Market mit Wirkung zum 8. Mai 2025 bekannt gegeben. Das Unternehmen, das Flüssigbiopsietests zur Früherkennung von Krebs entwickelt, behält seine DTC-Berechtigung für elektronische Abwicklung und Settlement in den USA bei. Die Aktie wird weiterhin an der Canadian Securities Exchange unter dem Symbol "BUX" gehandelt, ohne dass aktuelle Aktionäre Maßnahmen ergreifen müssen.
CEO Rashid Bux bezeichnete diesen Schritt als strategische Maßnahme zur Steigerung der Sichtbarkeit bei US-Investoren und zur Verbesserung der Aktienliquidität. Das Timing passt zu BioMarks Plänen, seinen Flüssigbiopsietest für Lungenkrebs kommerziell einzuführen und die Aktivitäten in den USA durch potenzielle Kooperationen mit umfassenden Krebs-Screening-Zentren auszubauen.
- Uplisting to OTCQB provides increased visibility and access to U.S. investors
- Maintains DTC eligibility, facilitating easier electronic trading and settlement
- Strategic timing coincides with upcoming commercial launch of lung cancer biopsy test
- Potential expansion into U.S. market through cancer screening center collaborations
- None.
Milestone strengthens transparency and credibility as the Company advances commercialization of its metabolomics technology platform
Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (OTCQB: BMKDF) (FSE: 20B) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that its common shares have been officially approved for uplisting from the OTC Pink Open Market to the OTCQB Venture Market under the symbol "BMKDF" on May 8th, 2025. Additionally, the Company's common shares will maintain its eligibility for settlement through the Depository Trust Company ("DTC"), a subsidiary of the Depository Trust & Clearing Corp., which facilitates the electronic clearing and settlement of publicly traded companies in the United States.
Trading on the OTCQB is expected to complement the Company's existing listing on the Canadian Securities Exchange (CSE) under its existing symbol "BUX" and no action is needed by current shareholders. Real-time quotes and market information on BioMark Diagnostics Inc. can be found at www.otcmarkets.com.
Rashid Bux, President and CEO, said: "This is a significant milestone for the Company as we aim to increase our presence among American retail and institutional investors, thereby providing enhanced liquidity. As we move toward the commercial launch of our liquid biopsy test for lung cancer, trading on the OTCQB will make it easier for U.S. investors to discover and trade our stock, while benefiting from transparent pricing and reporting standards. The timing is opportune for BioMark, and we believe the uplisting will boost visibility to a broader universe of investors and provide improved liquidity for our stock as the Company seeks to expand its future operations in the US, starting with potential collaborations at some important comprehensive cancer screening centers."
About OTCQB
The OTCQB® Venture Market is for entrepreneurial and development stage U.S. and international companies. The OTCQB is also the premier marketplace for developing companies, including those in the medical technology sector. To be eligible, companies must be current in their reporting and undergo an annual verification and comply with management certification requirements, providing investors with a trusted market for trading.
The OTCQX and OTCQB markets are considered 'Established Public Markets' by the SEC for the purpose of determining the public market price when registering securities for resale with the SEC in equity line financing. OTC Markets Group can facilitate electronic trading with its SEC-registered Alternative Trading System known as OTC Link ATS.
About BioMark Diagnostics Inc.
BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The Company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.
Further information about BioMark is available under its profile on the SEDAR+ website www.sedarplus.ca and the CSE website https://thecse.com/.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. This press release contains certain forward-looking statements, including statements regarding the anticipated benefits of the Company's OTCQB listing and DTC eligibility, the expected impact on trading liquidity, and the Company's ability to attract a broader U.S. investor base. Forward-looking statements include, but are not limited to, statements identified by words such as "expects", "anticipates", "believes", "intends", "will", "may", and similar expressions, which are intended to identify forward-looking statements.
Although the Company believes that its expectations as reflected in these forward-looking statements are reasonable, such statements involve risks and uncertainties, including but not limited to general market conditions, investor interest, regulatory changes, and other risk factors that could cause actual results to differ materially from those anticipated. There is no assurance that the OTCQB listing, or DTC eligibility will result in improved liquidity or broader investor access as anticipated.
The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements.
The CSE has not reviewed, approved, or disapproved of the content of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/251213
FAQ
What does BioMark Diagnostics' (BMKDF) uplisting to OTCQB mean for investors?
When will BioMark Diagnostics (BMKDF) begin trading on the OTCQB Venture Market?
What are BioMark Diagnostics' (BMKDF) expansion plans in the United States?
Do BioMark Diagnostics (BMKDF) shareholders need to take any action due to the OTCQB uplisting?
